Carl Ferguson, DO
Family Medicine · Mesa, AZNPI 1619068681
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $7,646 of the $10,558 with a category attached, or 72.4%. AbbVie accounts for 76.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $7,902 and has fallen 95.3% since, to $369 in 2025. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $66.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Amgen$513
- GSK$357
- AstraZeneca$311
- Novo Nordisk$272
- Impulse Dynamics (USA) Inc.$174
- plus $855 from 19 others
Across 3 payments — averaging $27,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$83K
What the payments were for
- Food & beverage$2,88827%
- Gifts$7,64672%
- Entertainment$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $8,079 |
| Amgen | 29 | $513 |
| GSK | 18 | $357 |
| AstraZeneca | 10 | $311 |
| Novo Nordisk | 21 | $272 |
| Impulse Dynamics (USA) Inc. | 1 | $174 |
| Lilly USA, LLC | 11 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $123 |
| Optinose US, Inc. | 5 | $104 |
| Pfizer | 4 | $63 |
| Abbott | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Braeburn Inc. | 2 | $45 |
| Antares Pharma, Inc. | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Orexo US, Inc. | 2 | $25 |
| Optos, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,558 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $70,395 |
| OzempicSemaglutide | 53 | $54,395 |
| EliquisApixaban | 45 | $52,926 |
| JardianceEmpagliflozin | 31 | $38,468 |
| TrulicityDulaglutide | 30 | $32,714 |
| FarxigaDapagliflozin Propanediol | 32 | $31,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $28,911 |
| NeuproRotigotine | 17 | $17,345 |
| Atorvastatin Calcium | 268 | $2,448 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,302 |
| Buprenorphine Hcl | 40 | $2,092 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $1,993 |
| Levothyroxine Sodium | 181 | $1,770 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $1,746 |
| Ezetimibe | 19 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $157 | $104,22190 claims |
| Novo NordiskOzempic | $272 | $54,39553 claims |
| PfizerEliquis | $63 | $52,92645 claims |
| AstraZenecaFarxiga | $311 | $31,37532 claims |
| GSKTrelegy Ellipta | $357 | $28,91129 claims |
| AbbVieSynthroid | $8,079 | $1,40916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Mesa
- Suzanne BentzMesa$174K
- Karen Acevedo MogharbelMesa$59K
- James GunnMesa$17K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.